These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3557190)

  • 1. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.
    Myers B; Evans DN; Rhodes J; Evans BK; Hughes BR; Lee MG; Richens A; Richards D
    Gut; 1987 Feb; 28(2):196-200. PubMed ID: 3557190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery and fate of oral mesalamine microgranules within the human small intestine.
    Layer PH; Goebell H; Keller J; Dignass A; Klotz U
    Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE; Rose GM; Conklin JD
    J Int Med Res; 1990; 18(6):441-53. PubMed ID: 1981363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
    Hussain FN; Ajjan RA; Riley SA
    Br J Clin Pharmacol; 2000 Apr; 49(4):323-30. PubMed ID: 10759687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal metabolism and transport of 5-aminosalicylate.
    Zhou SY; Fleisher D; Pao LH; Li C; Winward B; Zimmermann EM
    Drug Metab Dispos; 1999 Apr; 27(4):479-85. PubMed ID: 10101143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.
    Dew MJ; Ryder RE; Evans N; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1983 Aug; 16(2):185-7. PubMed ID: 6615691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
    Rasmussen SN; Bondesen S; Hvidberg EF; Hansen SH; Binder V; Halskov S; Flachs H
    Gastroenterology; 1982 Nov; 83(5):1062-70. PubMed ID: 7117789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability.
    Yu DK; Elvin AT; Morrill B; Eichmeier LS; Lanman RC; Lanman MB; Giesing DH
    Clin Pharmacol Ther; 1990 Jul; 48(1):26-33. PubMed ID: 2369807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.
    Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN
    Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine.
    Swift GL; Mills CM; Rhodes J; Evans BK; Bennett A; Tavares IA
    Aliment Pharmacol Ther; 1992 Apr; 6(2):259-66. PubMed ID: 1350926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].
    Keller J; Goebell H; Klotz U; Layer P
    Med Klin (Munich); 1998 May; 93(5):294-9. PubMed ID: 9630813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers.
    Brunner M; Greinwald R; Kletter K; Kvaternik H; Corrado ME; Eichler HG; Müller M
    Aliment Pharmacol Ther; 2003 May; 17(9):1163-9. PubMed ID: 12752353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.
    Klotz U; Maier KE; Fischer C; Bauer KH
    Arzneimittelforschung; 1985; 35(3):636-9. PubMed ID: 4039590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
    Mardini HA; Lindsay DC; Deighton CM; Record CO
    Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).
    De Mey C; Meineke I
    Br J Clin Pharmacol; 1992 Feb; 33(2):179-82. PubMed ID: 1550697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.